Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase 2/3 1Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Stomach Neoplasms 4Carcinoma, Hepatocellular 3Pancreatic Neoplasms 2Uterine Cervical Neoplasms 1Turcot syndrome 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Rectal Neoplasms 1Pancreatic Cancer Resectable 1Pancreatic Cancer Metastatic 1Neoplasms 1Multiple Primary Lung Cancer 1Metastatic Gastroesophageal Junction Adenocarcinoma 1Melanoma 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced Cervical Carcinoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1Advanced Solid Tumours 1Advanced Solid Tumor 1Advanced Intrahepatic Cholangiocarcinoma 1Advanced Biliary Tract Cancer 1Adenocarcinoma 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × sintilimab × Clear all
NCT05572463 2022-11-18

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Withdrawn
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡